Since decreased phosphatase function and increased kinase activity is a hallmark of cancer progression, we tested whether activating PP2A through SET antagonism, in combination with tyrosine kinase inhibitors, would reduce survival of T-ALL cells. The gene discussed is PTPA; the disease is acute lymphoblastic leukemia.